These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7919549)

  • 1. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells.
    Liebmann JE; Fisher J; Teague D; Cook JA
    Oncol Res; 1994; 6(1):25-31. PubMed ID: 7919549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cycloheximide inhibits the cytotoxicity of paclitaxel (Taxol).
    Liebmann J; Cook JA; Teague D; Fisher J; Mitchell JB
    Anticancer Drugs; 1994 Jun; 5(3):287-92. PubMed ID: 7919452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
    Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
    Liebmann JE; Hahn SM; Cook JA; Lipschultz C; Mitchell JB; Kaufman DC
    Cancer Res; 1993 May; 53(9):2066-70. PubMed ID: 8097674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.
    Adjei AA; Budihardjo II; Rowinsky EK; Kottke TJ; Svingen PA; Buckwalter CA; Grochow LB; Donehower RC; Kaufmann SH
    Clin Cancer Res; 1997 May; 3(5):761-70. PubMed ID: 9815747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
    Foroodi F; Duivenvoorden WC; Singh G
    Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
    Bible KC; Kaufmann SH
    Cancer Res; 1997 Aug; 57(16):3375-80. PubMed ID: 9269999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and radiotherapy: sequence-dependent efficacy--a preclinical model.
    Niero A; Emiliani E; Monti G; Pironi F; Turci L; Valenti AM; Marangolo M
    Clin Cancer Res; 1999 Aug; 5(8):2213-22. PubMed ID: 10473108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
    Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell line and schedule-dependent cytotoxicity of paclitaxel (Taxol): role of the solvent Cremophor EL/ethanol.
    Cordes N; Plasswilm L
    Anticancer Res; 1998; 18(3A):1851-7. PubMed ID: 9673415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.
    Nishio K; Ishida T; Arioka H; Kurokawa H; Fukuoka K; Nomoto T; Fukumoto H; Yokote H; Saijo N
    Anticancer Res; 1996; 16(6B):3387-95. PubMed ID: 9042196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Difluoromethylornithine antagonizes taxol cytotoxicity in MCF-7 human breast cancer cells.
    Das B; Rao AR; Madhubala R
    Oncol Res; 1997; 9(11-12):565-72. PubMed ID: 9563003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Izumi T; Mori K; Fujii H; Yazawa Y; Mano H; Furukawa Y
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel and N-methylformamide: in vitro interactions in human colon cancer cell line.
    Valenti AM; Niero A; Monti G; Marangolo F; Marangolo M
    Anticancer Res; 1997; 17(4A):2491-7. PubMed ID: 9252669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BrdUrd/DNA flow cytometry analysis demonstrates cis-diamminedichloroplatinum (II)-induced multiple cell-cycle modifications on human lung carcinoma cells.
    Demarcq C; Bastian G; Remvikos Y
    Cytometry; 1992; 13(4):416-22. PubMed ID: 1526199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
    Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
    Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
    Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
    Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
    Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.